5 Key Takeaways

• 1

  The AHRQ review may underrepresent the evidence base for prolonged grief disorder (PGD), impacting clinical care.

• 2

  Interpersonal psychotherapy for PGD shows a 71% response rate, significantly higher than the 44% for citalopram.

• 3

  The AHRQ review's grouping of heterogeneous psychotherapy studies may dilute the effectiveness signals for PGD-specific interventions.

• 4

  PGD is recognized in DSM-5-TR and has validated diagnostic tools and effective therapies demonstrated in randomized trials.

• 5

  Digital grief interventions show promise, but scalability and implementation challenges remain for PGD treatment.